CHICAGO - Radiation therapy developer Akesis is launching two new radiation therapy systems at this week's American Society for Radiation Oncology (ASTRO) meeting.
Akesis Galaxy RTi is a new gamma stereotactic radiosurgery (SRS) system that is based on Akesis Galaxy, which recently received 510(k) clearance from the U.S. Food and Drug Administration. Akesis Galaxy uses continuous 360° rotational technology, according to the company.
Akesis introduced Akesis Galaxy RTi at ASTRO 2019The new RTi model incorporates real-time in-line conebeam CT and kV/kV imaging for higher efficiency, and users will have the option of high-precision stereotactic radiosurgery or frameless, fractionated stereotactic radiotherapy (SRT).
The RTi system uses 30 gamma sources, which Akesis says can reduce the cost of ownership and minimize downtime during source replacement. The configuration also gives users more options to shape dose distribution versus traditional, fixed-sector radiation delivery, according to the company.
Akesis also disclosed at ASTRO 2019 that it is developing its first linear accelerator, Akesis Gemini360, which will use the same rotating gamma technology found in the Galaxy but in a ring gantry. The system will also sport a conventional 6-MV linear accelerator head and 120-leaf multileaf collimator that the company believes will give users the flexibility of a conventional radiotherapy treatment machine. Gemini360 will also include multiple in-line and real-time imaging options.
